Proactive Investors - Run By Investors For Investors

Circadian Technologies gains worldwide license from Chugai Pharmaceutical for VEGF-D applications

In a major shot in the arm for Circadian, the largest biopharmaceutical company in Japan, Chugai Pharmaceutical, a part of Roche has granted Circadian a global license to its vascular endothelial growth factor (VEGF) D intellectual property.
Circadian Technologies gains worldwide license from Chugai Pharmaceutical for VEGF-D applications

Cancer therapy drug developer Circadian Technologies (ASX: CIR) has received a major vote of confidence from biopharmaceutical global player Chugai Pharmaceutical, with worldwide VEGF-D intellectual property rights granted.

Chugai is part of the Roche Group of companies, 52% owned by Hoffman La-Roche.

With the deal, Circadian cements its position as a world leader in vascular endothelial growth factor (VEGF-D) development.

With Chugai's VEGF-D inventory, this enhances Circadian's ability to generate early revenues by using VEGF-D to develop new diagnostics and treatments.

VEGF-D is a major new target for cancer and other diseases including diagnostics for respiratory disease.

Importantly, the agreement allows Circadian to sub-licence which will enable the company to expand work in utilising the VEGF-D intellectual property estate through selective partnerships.

Consideration for the agreement is Circadian will pay an upfront licence fee to Chugai, and milestone payments and royalties on certain VEGF-D related products.

Robert Klupacs, chief executive officer of Circadian, said "It is a great honour for us that such a well regarded company as Chugai - a major player in Japan and part of the Roche group - has the confidence in our product development and commercialisation skills to grant us a licence to their intellectual property."

Chugai had revenues of $US4.6 billion in 2009.

 

View full OPT profile View Profile

Opthea Ltd Timeline

Related Articles

A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
1550834286_shutterstock_651647128.jpg
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use